Why A Congressional Subpoena To Valeant About Price Gouging On Drugs Should Be Granted

Why A Congressional Subpoena To Valeant About Price Gouging On Drugs Should Be Granted by Citron Research Short term price target $130 — Longer Term … worse. Note: This is part 1 in a multi-part story. While this note 1 discusses moral outrage over Valeant’s twisted strategic assault on the healthcare system, Part 2 will discuss the imminent danger of an over-levered balance sheet and why it will implode sooner than later. Note: This is not a biotech problem. It is a Valeant problem. The Real Risk to the US Healthcare System is when Health Care Costs are controlled by…